Protect Animal Health (寶泰生醫) unveiled three core innovation platforms at its investor conference on the 26th: AIRS (Gene therapy for canine heart disease), AIOT (Immuno-oncology for canine cancer), and its proprietary AIDE antibody platform. This dual-track strategy—combining in-licensing with internal R&D—aims to diversify risk and capture high-growth opportunities in the pet health sector.

Platform Breakdown:

1. AIRS (Advanced Integration Rejuvenation System): Targets the global canine heart disease market, estimated at over US$6 billion, addressing a high level of unmet clinical need.
2. AIOT (Affordable Immuno-Oncology Therapy): Features the product PT001 for canine oncology. With the global pet tumor market exceeding US$3 billion due to an aging pet population, Bioteque aims for a high-efficacy, accessible immunotherapy solution.
3. AIDE (Advanced Innovative Drug Engine): A proprietary, highly scalable whole-canine/feline antibody platform designed for long-term licensing and co-development value.

Chairman Sung Hao-lin emphasized that the future of pet medicine lies in applying "human-grade" technology to solve critical diseases, moving away from low-price competition.

Resource: 寶泰生醫發表寵物醫療三大創新平台，瞄準下一個長期成長生技賽道